REG - Solvonis Therapeutic - Allowance of U.S. patent covering AI-supported CNS

Solvonis TherapeuticsAnnouncement

23/06/2025 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250623:nRSW8613Na&default-theme=true

RNS Number : 8613N  Solvonis Therapeutics PLC  23 June 2025

23 June 2025
Solvonis Therapeutics plc

("Solvonis" or the "Company")

Allowance of U.S. patent covering AI-supported CNS discovery programme
compounds

 

Solvonis Therapeutics plc (LSE: SVNS), a clinical-stage biopharmaceutical
company developing novel medicines for addiction and mental health disorders,
is pleased to announce that the U.S. Patent and Trademark Office (the "USPTO")
has allowed a key patent application protecting compounds within the Company's
AI-enabled CNS discovery programme.

The application-U.S. No. 18/838,986, titled "Bridged Ring Compounds and Their
Therapeutic Use as CNS Agents"-received a first-action allowance with no
objections or rejections. The claims cover composition of matter and methods
of use for a family of novel morpholine-class compounds, originally developed
by Awakn Life Sciences Corp. and now central to Solvonis' Central Nervous
System ("CNS") library.

An "allowance" confirms that a patent will be granted, subject only to final
administrative steps.

The CNS library, which includes multiple chemically distinct, preclinically
validated series, underpins Solvonis' AI-supported drug discovery platform.
The patent adds meaningful protection across novel CNS chemical space,
especially in depression, stimulant use disorder and other neuropsychiatric
conditions.

The patent, expected to be granted in the coming months, will confer U.S.
exclusivity through to at least 2043, reinforcing the long-term value of
Solvonis' early-stage pipeline.

Professor David Nutt, Chief Scientific Officer of Solvonis, commented: "This
patent strengthens the foundation of our discovery platform and provides
long-term protection for a chemically distinct series of CNS-active compounds
already integrated into our AI-supported programme. The favourable examination
outcome reflects the novelty and robustness of the underlying chemistry, which
has now been further validated through translational screening and
computational analyses."

Anthony Tennyson, Chief Executive Officer of Solvonis, added: "We are
delighted by this outcome, which validates the early-stage innovation acquired
through Awakn and enhances the strategic value of our AI-enabled platform.
This grant provides additional confidence as we advance our discovery pipeline
targeting major unmet needs in neuropsychiatry."

 

Enquiries:

Solvonis Therapeutics plc

Anthony Tennyson, CEO & Executive Director

anthony@solvonis.com

Allenby Capital Limited (Financial Adviser and Joint Broker)

Nick Naylor / Nick Athanas / Ashur Joseph (Corporate Finance)

Guy McDougall (Sales & Corporate Broking)

+44 (0) 20 3328 5656

Singer Capital Markets (Joint Broker)

Phil Davies

+44 (0) 20 7496 3000

About Solvonis Therapeutics plc

Solvonis Therapeutics plc (LSE: SVNS) is a clinical-stage biopharmaceutical
company developing novel medicines for addiction and mental health disorders.
Headquartered in London and listed on the main market of the London Stock
Exchange, Solvonis is advancing a differentiated pipeline of repurposed and
novel compounds targeting high-burden neuropsychiatric conditions with
significant unmet need.

The Company's lead programmes address Alcohol Use Disorder (AUD) and
Post-Traumatic Stress Disorder (PTSD)-conditions affecting over 80 million
people across the UK, US, and EU4. Its lead asset, SVN-001, is currently in
Phase 3 for severe AUD in Europe and the UK. SVN-002 is preparing for a Phase
2b trial in the US targeting moderate to severe AUD. Solvonis also has a
preclinical PTSD programme leveraging novel serotonin-dopamine modulators
designed to enhance pro-social behaviour and long-term outcomes.

In addition, Solvonis is advancing an AI-supported discovery platform built on
a proprietary CNS compound library, with initial focus on depression and
stimulant use disorders. This initiative expands the Company's R&D
pipeline into earlier-stage innovation while maintaining strategic focus on
comorbid and underserved neuropsychiatric conditions.

With a capital-efficient model, dual development strategy, and near-term
partnering opportunities, Solvonis is positioned to generate value through
innovation in neuropsychiatry.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  UPDFBMLTMTMTMJA